Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S(2025) Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis Am J Hematol(in press) DOI 10.1002/ajh.27661, PubMed 40143674
Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F(2025) Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial Lancet Haematol, 12(2), e120-e127 DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655
Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele Het al.(2025) International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma Leukemia, 39(3), 543-554 DOI 10.1038/s41375-024-02482-6, PubMed 39870767